<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 12, 2020 (HealthDay News) — For patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) treated with pertuzumab and\/or trastuzumab emtansine (T-DM1), a body mass index (BMI) of \u226530 kg\/m\u00b2 is associated with worse overall survival but does not affect progression-free survival to first-line chemotherapy (PFS1), according to a study published online Jan. 15 in the Journal of Cellular Physiology<\/i>.<\/p>\n
Eriseld Krasniqi, M.D., from the IRCCS Regina Elena National Cancer Institute in Rome, and colleagues examined the influence of BMI on clinical outcomes of 709 patients with HER2+ mBC treated with pertuzumab and\/or T-DM1. The influence of BMI was further analyzed among 575 women who progressed to first-line chemotherapy.<\/p>\n
The researchers found that BMI had no impact on PFS1 overall, while BMI \u226530 kg\/m\u00b2 was associated with significantly worse overall survival. BMI \u226530 kg\/m\u00b2 had a detrimental effect on overall survival for the women within PFS1 quartile I (PFS1 no more than six months) in a univariate analysis. In a multivariable analysis, the results were confirmed. According to PFS1 quartiles, within six months of therapy, a higher percentage of patients with high BMI and low disease burden progressed.<\/p>\n
“In this particularly challenging battlefield, namely, in the HER2+ metastatic breast cancer, a well-depicted patient profile, including details on body mass index and its prognostic relevance, can help inform therapeutic decisions,” Krasniqi said in a statement.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n